Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.47 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20849165 | 0.97 | AR (0.45) | AREDNRBEDNRAPGRCYP2C9 | |
| SCHEMBL22985625 | 0.93 | AR (0.43) | ARPGRBCAT1TSHRSMN1; SMN2 | |
| SCHEMBL20849519 | 0.93 | AR (0.40) | AREDNRBEDNRAPGRCYP2C9 | |
| SCHEMBL20849012 | 0.93 | AR (0.38) | AREDNRBEDNRAPGRCYP2C9 | |
| SCHEMBL22985127 | 0.91 | AR (0.47) | ARPGRPDE3BPDE3A | |
| SCHEMBL20849102 | 0.91 | AR (0.48) | AREDNRBEDNRAPGRCYP2C9 | |
| SCHEMBL20848739 | 0.91 | AR (0.38) | AREDNRBEDNRAPGRCYP2C9 | |
| SCHEMBL20849159 | 0.91 | AR (0.38) | AREDNRBEDNRAPGRCYP2C9 | |
| SCHEMBL22985622 | 0.91 | AR (0.41) | ARPGRBCAT1TSHRSMN1; SMN2 | |
| SCHEMBL21399693 | 0.90 | AR (0.44) | ARPGRBCAT1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10978646-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20190097141-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10978646-B2 | Organic molecules for use in optoelectronic devices | OCIAD2, OCIAD1, POU2F1 | AR 3706/4885EDNRB 1908/4885EDNRA 2566/4885 |
| US-20190097141-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OCIAD2, OCIAD1, POU2F1 | AR 3706/4885EDNRB 1908/4885EDNRA 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.